Human Genome Sciences (HGS) Inc announced early results in BLISS-52 trial using BENLYSTA (belimumab, formerly LymphoStat-B). The results have left them blissful as the study results showed patients who took Benlysta demonstrated a statistically significant improvement in the symptoms of their disease compared with those taking a placebo.
Human Genome Sciences (HGS) Inc announced early results in BLISS-52 trial using BENLYSTA (belimumab, formerly LymphoStat-B). The results have left them blissful as the study results showed patients who took Benlysta demonstrated a statistically significant improvement in the symptoms of their disease compared with those taking a placebo.
Source:
Ramona Bates MD 
